Completed PHASE1 INTERVENTIONAL 3-arm NCT05806567

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

A Three-part, Sequential, Non-randomized, Open-label Study Designed to Evaluate the Effect of Oral Belumosudil on UGT1A1, P-gp, BCRP and OATP1B1 Inhibition in the Fed State in Healthy Male Subjects

Sponsor: Kadmon, a Sanofi Company

Conditions Healthy Volunteers Immune System Disorder

Interventions Belumosudil OATP1B1/BCRP victim drug P-gp victim drug UGT1A1 victim drug

Updated 5 times since 2023 Last updated: Sep 21, 2025 Started: Jul 27, 2022 Primary completion: Oct 20, 2022 Completion: Oct 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers and Immune System Disorder, this trial is completed. The trial is conducted by Kadmon, a Sanofi Company and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Oct 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1
May 2023 — Aug 2023 [monthly]

Completed PHASE1

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kadmon, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States